Reviewer’s report

Title: Association of serum C1q/TNF-related protein-3 (CTRP-3) in patients with coronary artery disease

Version: 0 Date: 30 May 2017

Reviewer: Gideon Charach

Reviewer’s report:

The study has some interest.

I would like to understand why we need this biomarker. There are many biomarkers. Why it is better than CRP, BNP, oxidized LDL, LDL, HDL, total cholesterol, lymphocytes count IL-6, TNF etc.? Please explain.

I would expect to compare several other biomarkers with CTRP 3 and to show which of them has higher predictive value for diagnosis and prognosis.

Is there any data about statins impact on CTRP 3 levels.

The laboratory assay is not simple. Is it practical and cost effective to use Plasma CTRP 3?

Methods section: Exclusion criteria - why patients with acute myocardial infarction were excluded? So many exclusions. It looks that the Plasma CTRP 3 can be used only in small selected number of patients.

There were significant differences in % glucose levels, systolic HTN, and BMI which are significant risk factors. There was difference in HDL levels.

Can you provide cut point levels of CTRP 3 which can predict CAD?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Unable to assess

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests' below.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal